All news

Castle Biosciences CCO files to sell 13,154 shares

Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash

Castle Biosciences Chief Commercial Officer Tobin Juvenal filed a Form 144 notice to sell 13,154 common shares through Goldman Sachs & Co. LLC, valued at roughly $430,925.04. The sale runs under a 10b5-1 plan dated May 28, 2026, with an anticipated sale date of October 12, 2026, on shares acquired from Restricted Stock Units and Awards granted in late 2023..

Read original source

CSTL company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.